Cardiff Oncology Q3 Earnings Outperform Expectations with $11.3M Loss and $120K Revenue

Cardiff Oncology reported a Q3 loss of $11.3 million, or 17 cents per share, beating analyst expectations of a 20-cent loss. Revenue was $120,000. The molecular diagnostic company's results topped Wall Street expectations, with the average estimate from four analysts surveyed by Zacks Investment Research being a loss of 20 cents per share.